399 related articles for article (PubMed ID: 28646513)
1. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era.
Berry JL; Shah S; Bechtold M; Zolfaghari E; Jubran R; Kim JW
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28646513
[TBL] [Abstract][Full Text] [Related]
2. Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in Retinoblastoma.
Berry JL; Bechtold M; Shah S; Zolfaghari E; Reid M; Jubran R; Kim JW
Ophthalmology; 2017 Dec; 124(12):1817-1825. PubMed ID: 28655537
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
4. Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy for retinoblastoma with vitreous seeds.
Lee JH; Han JW; Hahn SM; Lyu CJ; Kim DJ; Lee SC
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):391-4. PubMed ID: 26511530
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.
Berry JL; Jubran R; Kim JW; Wong K; Bababeygy SR; Almarzouki H; Lee TC; Murphree AL
Pediatr Blood Cancer; 2013 Apr; 60(4):688-93. PubMed ID: 22997170
[TBL] [Abstract][Full Text] [Related]
6. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.
Shields CL; Alset AE; Say EA; Caywood E; Jabbour P; Shields JA
J Pediatr Ophthalmol Strabismus; 2016 Sep; 53(5):275-84. PubMed ID: 27486728
[TBL] [Abstract][Full Text] [Related]
7. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan.
Francis JH; Abramson DH; Gaillard MC; Marr BP; Beck-Popovic M; Munier FL
Ophthalmology; 2015 Jun; 122(6):1173-9. PubMed ID: 25795478
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications.
Munier FL; Gaillard MC; Balmer A; Soliman S; Podilsky G; Moulin AP; Beck-Popovic M
Br J Ophthalmol; 2012 Aug; 96(8):1078-83. PubMed ID: 22694968
[TBL] [Abstract][Full Text] [Related]
9. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F; Shields CL; Ghadimi H; Khodabandeh A; Roohipoor R
JAMA Ophthalmol; 2014 Aug; 132(8):936-41. PubMed ID: 24789622
[TBL] [Abstract][Full Text] [Related]
10. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
11. [Short-term efficacy of intravitreal injection of melphalan for refractory vitreous seeding from retinoblastoma].
Xue K; Ren H; Zhang R; Yuan YF; Qian J
Zhonghua Yan Ke Za Zhi; 2017 Aug; 53(8):570-574. PubMed ID: 28851196
[No Abstract] [Full Text] [Related]
12. Diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report.
Chao A; Kao LY; Liu L; Wang NK
BMC Ophthalmol; 2016 Mar; 16():27. PubMed ID: 26975871
[TBL] [Abstract][Full Text] [Related]
13. INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture.
Shields CL; Douglass AM; Beggache M; Say EA; Shields JA
Retina; 2016 Jun; 36(6):1184-90. PubMed ID: 26630319
[TBL] [Abstract][Full Text] [Related]
14. INTRAVITREAL MELPHALAN AS SALVAGE THERAPY FOR REFRACTORY RETINAL AND SUBRETINAL RETINOBLASTOMA.
Francis JH; Marr BP; Brodie SE; Gobin P; Dunkel IJ; Abramson DH
Retin Cases Brief Rep; 2016; 10(4):357-60. PubMed ID: 26630243
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma.
Kiratli H; Koç İ; Varan A; Akyüz C
Eur J Ophthalmol; 2017 Jun; 27(4):423-427. PubMed ID: 28106239
[TBL] [Abstract][Full Text] [Related]
16. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
Shields CL; Ramasubramanian A; Thangappan A; Hartzell K; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal Lower-Dose (20 µg) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds.
Tuncer S; Balcı Ö; Tanyıldız B; Kebudi R; Shields CL
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):942-8. PubMed ID: 26469234
[TBL] [Abstract][Full Text] [Related]
18. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.
Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH
Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859
[TBL] [Abstract][Full Text] [Related]
19. Intra-Arterial Chemotherapy for Retinoblastoma: A Single-Center Experience.
Akyüz C; Kıratlı H; Şen H; Aydın B; Tarlan B; Varan A
Ophthalmologica; 2015; 234(4):227-32. PubMed ID: 26368674
[TBL] [Abstract][Full Text] [Related]
20. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds.
Shields CL; Bianciotto CG; Jabbour P; Ramasubramanian A; Lally SE; Griffin GC; Rosenwasser R; Shields JA
Arch Ophthalmol; 2011 Nov; 129(11):1399-406. PubMed ID: 21670328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
